Pharmaceutical - Immunologicals, Research

Filter

Current filters:

ImmunologicalsResearch

Popular Filters

1 to 25 of 43 results

Link between immune system and brain diseases to be researched by Lundbeck

22-12-2014

Danish CNS specialist drugmaker Lundbeck is involved in new groundbreaking research that will investigate…

ImmunologicalsJanssenLundbeckNeurologicalPharmaceuticalResearch

ADMA’s lead product meets primary endpoint in Phase III trial

04-12-2014

US-based biopharmaceutical company ADMA Biologics says that its lead product candidate RI-002 has demonstrated…

ADMA BiologicsImmunologicalsPharmaceuticalResearchRI-002USA

GlaxoSmithKline drops option for Dynavax’ DV1179

28-11-2014

USA-based Dynavax Technologies (Nasdaq: DVAX) today announced that it has regained full rights to DV1179,…

DV1179Dynavax TechnologiesGlaxoSmithKlineImmunologicalsLicensingPharmaceuticalResearch

Sanofi showcases next wave of medicines and vaccines

20-11-2014

French pharma major Sanofi is today outlining its intention to launch high-potential new medicines and…

Cardio-vascularDiabetesHealth Medical PharmaImmunologicalsNeurologicalPharmaceuticalPharmaceutical industryRare diseasesResearchSanofiUnited StatesVaccines

AstraZeneca and University of Glasgow partner to form immunology discovery center

AstraZeneca and University of Glasgow partner to form immunology discovery center

04-11-2014

The University of Glasgow and Anglo-Swedish drug major AstraZeneca have now officially launched the GLAZgo…

AstraZenecaImmunologicalsPharmaceuticalResearchUK

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

02-10-2014

US pharma major Eli Lilly has said it will discontinue development of tabalumab, which is being studied…

Anti-Arthritics/RheumaticsEli LillyImmunologicalsPharmaceuticalResearchtabalumabUSA

Pfizer and Kyowa Hakko collaborate on immuno-oncology combination study

Pfizer and Kyowa Hakko collaborate on immuno-oncology combination study

30-09-2014

US pharma major Pfizer and Japanese drugmaker Kyowa Hakko Kirin have entered into an agreement to explore…

ImmunologicalsKyowa Hakko KirinmogamulizumabOncologyPF-05082566PfizerPharmaceuticalResearchUSA

Takeda and BioMotiv in strategic partnership, including investment

Takeda and BioMotiv in strategic partnership, including investment

25-09-2014

Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv,…

BioMotivCardio-vascularFinancialImmunologicalsInflammatory diseasesJapanPharmaceuticalResearchTakeda PharmaceuticalUSA

Merck Serono on track with pharma strategy

Merck Serono on track with pharma strategy

18-09-2014

Germany’s Merck KGaA says that its biopharmaceutical division - Merck Serono - is well on track with…

ataciceptBiosimilarsFinancialGermanyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearchTH-302

New UK report finds divide between personalized medicines R&D and regulatory environment

New UK report finds divide between personalized medicines R&D and regulatory environment

11-04-2014

Over half of the active products in the global industry research pipeline are personalized medicines…

Chief executiveHealth Medical PharmaHealthcareImmunologicalsPharmaceuticalPharmaceutical sciencesPharmacologyResearchStephen WhiteheadUK

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

ALK’s partner for Japan reports positive trial results for house dust mite SLIT-tablet

10-03-2014

Denmark-based allergy specialist ALK Abello said that its Japanese partner Torii Pharmaceutical has reported…

ALK AbelloDenmarkImmunologicalsJapanPharmaceuticalResearchTorii Pharma

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

05-03-2014

Swiss drug major Roche has presented new data from the LUTE / VERSE Phase IIb studies for the investigational…

ImmunologicalslebrikizumabPharmaceuticalResearchRespiratory and PulmonaryRocheUSA

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

05-03-2014

Pharma giant Merck & Co has announced results from a Phase IIb study evaluating two doses of its investigational…

ImmunologicalsMerck & CoPharmaceuticalResearchUSA

Stallergenes links with ActoGeniX on new class of oral allergy treatments

03-12-2013

French allergen specialist Stallergenes and ActoGeniX NV, creator of ActoBiotics, have entered into an…

ActoBioticsActoGeniXImmunologicalsLicensingPharmaceuticalResearchStallergenes

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

12-11-2013

US pharma giant Merck & Co (NYSE: MRK) has published positive results for its investigational Timothy…

ALK AbelloGrazaxImmunologicalsMerck & CoNorth AmericaPharmaceuticalResearchUSA

Pfizer says Rapamune failed endpoints in renal transplant study

Pfizer says Rapamune failed endpoints in renal transplant study

09-11-2013

US pharma behemoth Pfizer released disappointing top-line results from a Phase IIIb/IV study of its already-marketed…

ImmunologicalsPfizerPharmaceuticalRapamuneResearch

Stallergenes and DBV Technologies collaborate in birch pollen allergy research

18-10-2013

French allergy specialists Stallergenes and DBV Technologies, creator of Viaskin for the treatment of…

DBV TechnologiesImmunologicalsPharmaceuticalResearchRespiratory and PulmonaryStallergenes

Novartis links with Regenerex in cell therapy research collaboration

06-09-2013

Swiss drug major Novartis (NOVN: VX) has entered into an exclusive global licensing and research collaboration…

BiotechnologyCTL019HSC835ImmunologicalsLicensingNovartisPharmaceuticalRegenerexResearch

Swedish researcher report on unexpected use of former cancer drug

29-08-2013

Researchers at Sweden's Lund University have unexpectedly discovered that an old cancer drug - zebularine…

ImmunologicalsOncologyPharmaceuticalResearchzebularine

Teijin and Amgen join forces on autoimmune disease research

31-07-2013

Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

Merck Serono sets up new platform for cancer therapies innovation

26-06-2013

Merck Serono, the biopharmaceutical division of Germany's Merck KGaA (MRK: DE) says it has created a…

BiotechnologyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Positive Ph III findings on ALK's new house dust mite allergy immunotherapy; EU filing expected in 2014

20-06-2013

Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced positive outcome of the first of…

ALK AbelloImmunologicalsPharmaceuticalRegulationResearchRespiratory and Pulmonary

1 to 25 of 43 results

Back to top